A significant shareholder always has an interest in talking up one’s own stock, but this post below seems a little extra. I and other forum members would sure appreciate your thoughts on what happened @antibotter. I think that is only fair and reasonable. Poor form if you don’t.
This is substantiated information below. It is Hotcopper post ref 02/01/19 17:25 Post #: 37005569
”So there are absolutely no misunderstandings. All this was confirmed by management to me in conversation last week...... Dep Cabazitaxel will be licenced out before initiation of P2 clinical trial (in other words this year.)” ~ @antibotter in 2019
DEP-Cabazitaxel, page-8
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.7¢ |
Change
-0.003(3.00%) |
Mkt cap ! $40.90M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.7¢ | $38.04K | 388.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 21188 | 9.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.8¢ | 39367 | 3 |
View Market Depth
| Last trade - 15.56pm 03/10/2024 (20 minute delay) ? |
| SPL (ASX) Chart |